Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.52 |
| ▸ | DHODH | Q02127 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Menaquinone 7 SCHEMBL15438185 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL10055449 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL14164356 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL8709976 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| Menaquinone 7 SCHEMBL436068 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| Menatetrenone SCHEMBL571912 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| Menatetrenone SCHEMBL8703544 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL571907 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| Menaquinone 6 SCHEMBL244452 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL14164358 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082198-A1 | STABILIZED ALKYL NITRITE COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20140031432-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K | AMPERE LIFE SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031432-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K | AMPERE LIFE SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031432-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K | AMPERE LIFE SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2012019032-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K | AMPERE LIFE SCIENCES, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082198-A1 | STABILIZED ALKYL NITRITE COMPOSITIONS | NDUFV2, NOS2, NDUFS3 | PTGS1 524/4885PDE4A 1109/4885SNCA 463/4885 |
| US-20140031432-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K | FH, COQ8A, BCKDK | PTGS1 2269/4885PDE4A 2847/4885SNCA 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.